Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 19, 2025Renal FailureOpen Access

Astragaloside IV reduces diabetic kidney injury by inhibiting the PKC/NOX4/MAPK pathway

View Full Paper
Ask AI
Bookmark
Share

Authors

WBWenhan BaiYYYuan YangLWLimin Wang

Discussion

Loading...

Member takes

Overview

Animal study reveals astragaloside IV improves kidney health in diabetic rats, suggesting potential therapies for diabetic nephropathy.

Key Points

  • Astragaloside IV treatment significantly improved kidney function and reduced injury in diabetic rats, indicating strong protective effects.
  • Administering astragaloside IV at varying doses for 13 weeks led to notable changes in blood glucose, lipids, and glomerular filtration rates.
  • This study utilized a rat model of type 2 diabetes, focusing on the PKC/NOX4/MAPK pathway to explore underlying protective mechanisms.
  • Findings highlight the potential of astragaloside IV as a therapeutic candidate for diabetic nephropathy and related renal injuries.

Cite This Study

Bai et al. (2025) studied this question.

synapsesocial.com/papers/68d437f7713b0b5dfea778aahttps://doi.org/10.1080/0886022x.2025.2557019
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Astragaloside IV Improves Diabetic Kidney Disease by Regulating NLRP3 Inflammasome2025
  2. 2Astragalus polysaccharide alleviates diabetic nephropathy via SIRT1-dependent activation of FOXO3a/BNIP3 pathway to enhance podocyte autophagy2025 · 2 citations
  3. 3Astragaloside IV attenuates uremia-induced myocardial injury by inhibiting autophagy via ATF42025
  4. 4Metabolite‐Guided Acetylation Therapy: Astragaloside IV Reverses Diabetic Nephropathy via Gna13‐Driven Purine Metabolic Reprogramming2025
  5. 5Astragaloside IV inhibits MAPK pathway and promotes mitochondrial autophagy in rats with heart failure2025